ALS Center News National

Tofersen demonstrates positive results in Phase I/II trial for amyotrophic lateral sclerosis

View Content

Biogen (MA, USA) has announced positive results from a Phase I/II study of tofersen – an antisense oligonucleotide – for the potential treatment of SOD1 amyotrophic lateral sclerosis (ALS). These results have been published in The New England Journal of Medicine.